Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Alkynyl alcohols and methods of use
US9605005B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605005-B2 |
| Application number | US-201615074100-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 18, 2016 |
| Priority date | Aug 22, 2013 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of Formula (0): wherein Q, A 1 -A 8 , R 4 and R 5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the following: 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient. 3. A method for the treatment of an inflammatory condition in a patient, comprising administering an effective amount of a compound of claim 1 to the patient. 4. The method of claim 3 , wherein the inflammatory condition is selected from the group consisting of lupus, systemic lupus erythematosus, COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatitis, endometriosis and transplant rejection.
Assignees
Inventors
Classifications
Immunomodulators · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for immunological or allergic disorders · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9605005B2 cover?
- The invention relates to compounds of Formula (0): wherein Q, A 1 -A 8 , R 4 and R 5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired …
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).